5'-Ethylcarboxamido-adenosine
NECA
1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl-b-D-ribofuranuronamide
5'-Ethylcarboxamido-D-adenosine
| Catálogo Nº | Apresentação | Preço (R$) | Comprar / Observação |
|---|---|---|---|
| N-1076 | 200 μl (1 mM) | Sob demanda | Adicionar ao Carrinho |
For research use only!
Envio: shipped at ambient temperature
Condições de armazenamento: store at 4 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.
Validade: 24 months after date of delivery
Fórmula molecular: C12H16N6O4
Peso molecular: 308.29 g/mol
CAS#: 35920-39-9
Pureza: ≥ 95 % (HPLC)
Forma: solution in DMSO
Concentração: 1 mM
Formulários:
Binding studies, physiological studies on cell cultures or tissues and in animal experiments.
Compound has highest activity to nucleoside receptor type A1 and a less extent to A2A and A3.
Usage: Dissolve stock solution with aqueous physiological buffer recommended for displacement studies, biochemical signal transduction studies or animal experiments.
To avoid biological effects of DMSO dilute the stock solutions with aqueous buffers to a content of DMSO below 1 %.
Please note: Stable in acidic and neutral buffer solutions for one day
Referências selecionadas:
Nemeth et al. (2007) Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 21:2379.
Joshi et al. (2005) Purine derivatives as ligands for A3 adenosine receptors. Current Topics in Medicinal Chemistry 5:1275.
Nemeth et al. (2005) Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J. Immunology 175:8260.
Wittendorp et al. (2004) The mouse brain adenosine A1 receptor: functional expression and pharmacology. Europ. J. Pharmacol. 487:73.
Knapp et al. (2001) Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 68 (4):797.
Hess (2001) Recent advantages in adenosine receptor antagonist research. Expert Opin. Ther. Patents 11 (10):1533.
Merighi et al. (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Brit. J. Pharmacol. 134:1215.
Klotz et al. (1998) Comparative pharmacology of human adenosine receptor subtypes – characterization of stable transfected receptors in CHO cell. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1.
Van Galen et al. (1994) A binding site model and structure-activity relationships for rat A3 adenosine receptor. Molecular Pharmacology 45:1101.
Cusack et al. (1981) 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br. J. Pharmacol. 72 (3):443.